Clinical trials: Pituitary Cancer
Acromegaly
A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.
If someone is diagnosed with a pituitary tumor that causes acromegaly (too much growth hormone) the treatment is to have it surgically removed. This study has two phases.
- Trial name
- NCT01861717
- Testing
- lanreotide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Saint John's Cancer Institute
Pituitary Adenomas
Predictive Factors of Recurrence of Non Functioning Pituitary Adenomas : a Retrospective Study of 220 Patients in the Reims University Hospital, France
Non functioning pituitary adenomas (NFPAs) are the most common pituitary adenomas. Their growth is usually slow and diagnosis is often made in the context of masse effect .The therapeutic alternatives are surgery and radiotherapy…
- Trial name
- NCT02803697
- Testing
- Patients
- Where
- France
- Volunteers
- 106 people
- Sponsor
- CHU de Reims
Adrenal Insufficiency, Leukemia, Lymphoblastic, Acute, Pediatric
A Swiss Assessment of Hypothalamic-pituitary-adrenal Axis Suppression After Glucocorticoid Therapy for Leukemia and Lymphoblastic Lymphoma in Children
Plain Language Summary: Background Glucocorticoids are stress hormones produced by the human body to control inflammation and regulate the immune system. Cortisol is the most well-known example of a glucocorticoid.
- Conditions
- Adrenal Insufficiency, Leukemia, Lymphoblastic, Acute, Pediatric, Lymphoma, Lymphoblastic
- Trial name
- LeukemiaCort (NCT06861530)
- Where
- 2 sites in Switzerland
- Volunteers
- 40 people
- Sponsor
- University Children's Hospital Basel
Acromegaly
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
This study will investigate the efficacy of a combination treatment with octreotide acetate and cabergoline in acromegalic patients that are only partially responsive to a somatostatin analog monotherapy
- Trial name
- NCT00376064
- Testing
- Octreotide acetate and cabergoline/Octrotide and Somavert
- Where
- 16 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Grade I Meningioma, Grade II Meningioma
Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors.
- Conditions
- Grade I Meningioma, Grade II Meningioma, Grade III Meningioma, Intracranial Neoplasm
- Trial name
- HiPPI (NCT04278118)
- Testing
- Hypofractionated Radiation Therapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Emory University
Colon Cancer Liver Metastasis, Inflammatory Response
Argipressin's Influence on Blood Loss During Hepatic Resection
Infusion of Argipressin during hepatic resection surgery may reduce blood loss. It may also reduce transfusion requirements, and mitigate the perioperative inflammatory response compared to placebo.
- Conditions
- Colon Cancer Liver Metastasis, Inflammatory Response, Vasopressin Causing Adverse Effects in Therapeutic Use
- Trial name
- ARG-01 (NCT05293041)
- Testing
- Argipressin
- Where
- Sweden
- Volunteers
- 248 people
- Sponsor
- Kristina Svennerholm
Pain, Postoperative, Analgesia
Analgesia Nociception Index (ANI) in Intracranial Surgical Anesthesia
In our study, 75 patients aged 18-80 years, classified as ASA I-II risk groups, who underwent intracranial surgery performed by the Department of Neurosurgery at Trakya University Faculty of Medicine Hospital, were included.
- Conditions
- Pain, Postoperative, Analgesia, Supratentorial Brain Tumor, Infratentorial Neoplasms
- Trial name
- ANI (NCT06752824)
- Testing
- ANALGESIA NOCICEPTION INDEX MONITORING
- Where
- Turkey (Türkiye)
- Volunteers
- 75 people
- Sponsor
- Trakya University
Surgery, Pituitary Adenoma
Comparative Effectiveness of Different Surgical Approaches for Giant Pituitary Adenomas
The surgical treatment strategy for giant invasive pituitary adenoma is one of the current hot spots in the field of clinical research on pituitary adenoma.
- Trial name
- NCT05448690
- Testing
- Two different approaches, Non-combined approach
- Where
- 13 sites in China
- Volunteers
- 600 people
- Sponsor
- Huashan Hospital
Pituitary Adenoma
Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)
To study the in vivo expression of dopamine D2 receptors in nonfunctioning pituitary adenoma and the predictive role of dopamine dopamine D2 receptors PET-MR imaging in the therapeutic effect of dopamine agonists（DA）.
- Trial name
- NCT03714763
- Testing
- Drug treatment, Surgery
- Volunteers
- 50 people
- Sponsor
- Zhebao Wu
Oncology Pain
Pituitary Gland Stimulation for Cancer Pain Relief
Patients will undergo an implantation of an extradural pituitary surface electrode in the pituitary fossa. The electrode will be attached to a neurostimulator via which the patient will receive up to 8 (patient requested)…
- Trial name
- PGS (NCT05230238)
- Testing
- Pituitary gland stimulation
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Leiden University Medical Center
Cushing's Disease, Acromegaly
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
- Conditions
- Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors
- Trial name
- NCT01794793
- Testing
- Pasireotide, Cabergoline, Pasireotide LAR
- Where
- 94 sites in United States, Argentina and 26 more
- Volunteers
- 337 people
- Sponsor
- RECORDATI GROUP
Prolactinoma
Exercise Capacity and Physical Activity Level in Prolactinoma Patients
Prolactinoma, one of the most common pituitary adenomas, is an adenoma that causes excessive prolactin (PRL) secretion. An increase in prolactin level can cause weakness, decrease in muscle mass and fatigue.
- Trial name
- NCT05236829
- Where
- Turkey (Türkiye)
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion
SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome
This is a randomized, placebo-controlled, study of SPI-62 in subjects with ACTH-dependent Cushing's syndrome caused by a non-adrenal tumor.
- Conditions
- Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion
- Trial name
- RESCUE (NCT05307328)
- Testing
- SPI-62
- Where
- 12 sites in United States, Bulgaria and 1 more
- Volunteers
- 26 people
- Sponsor
- Sparrow Pharmaceuticals
Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
This phase II trial studies how well 177Lu-DOTATATE works in treating patients with rare endocrine cancers that have spread from where they started to nearby tissue or lymph nodes (locally advanced), spread to other places in the…
- Conditions
- Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma
- Trial name
- NCT04106843
- Testing
- Lutetium Lu 177 Dotatate
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Panhypopituitarism, Craniopharyngioma
The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study
GLP-1 analogs are used as agents in the existing treatment of obesity. However, there are lack of previous reports on the effectiveness and role of GLP-1 analogs in the development of obesity traits in patients with functionally…
- Conditions
- Panhypopituitarism, Craniopharyngioma, Hypothalamic Obesity
- Trial name
- NCT06217848
- Testing
- Saxenda
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Seoul National University Hospital
Cushing Disease, ACTH-producing Pituitary Tumour
Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors.
Cushing's disease results from adrenocorticotropic hormone (ACTH) secretion by corticotroph pituitary neuroendocrine tumors (PitNETs).
- Trial name
- PiTFET (NCT07463625)
- Testing
- Data-only evaluation of [18F]FET PET, pituitary MRI, and biomarkers
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Non-functioning Pituitary Adenoma
Effect of Dexmedetomidine on Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Surgery
In multiple previous studies that have explored the use of dexmedetomidine in transsphenoidal tumor resection surgery, dexmedetomidine showed many beneficial effects like reducing the requirement of analgesics and anesthetics…
- Trial name
- NCT05005715
- Testing
- Dexmedetomidine, normal saline
- Where
- South Korea
- Volunteers
- 64 people
- Sponsor
- Seoul National University Hospital
Pituitary Adenoma, Nonfunctioning Pituitary Adenoma
Cabergoline in Nonfunctioning Pituitary Adenomas
Clinically nonfunctioning pituitary adenoma remains the only pituitary tumor subtype for which no effective medical therapy is available or recommended.
- Trial name
- NCT03271918
- Testing
- Cabergoline
- Where
- Brazil
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Acromegaly
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
This is a phase IIIb multicenter, open-label; single arm study to evaluate the efficacy and safety of pasireotide LAR 40 mg and 60 mg in patients with inadequately controlled acromegaly with maximal approved doses of first…
- Trial name
- NCT02354508
- Testing
- Pasireotide LAR
- Where
- 50 sites in Argentina, Belgium and 13 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals